Personalized medicine also known as precision medicine is transforming pharmaceutical research by shifting from a “one-size-fits-all” model to tailored treatments based on an individual’s genetic makeup. Advances in genomics over the past two decades have made it possible to identify genetic drivers of disease and drug response, and now artificial intelligence (AI) is amplifying these insights. The convergence of AI and genomics promises to equip pharma companies with powerful tools to develop targeted therapies faster, improve patient outcomes, and reduce the trial-and-error in prescribing. In fact, the momentum behind this approach is evident: according to the Personalized Medicine Coalition, 34% of all new medicines approved by the FDA in 2022 were personalized therapies a dramatic rise that underscores the growing importance of genomics-guided drugs. ¹
This article explores the evolution of personalized medicine in pharma and how AI is accelerating genomics-based R&D, with case studies, regulatory implications, and a look at the global landscape including China’s ambitious strides in AI-powered precision medicine.
Evolution of Personalized Medicine and Genomics in Pharma
Personalized medicine isn’t brand new, it's been around for a while. But thanks to recent scientific advances, it’s now becoming a big part of how new medicines are developed. Unlike traditional treatments that are designed for the "average" patient, personalized medicine focuses on tailoring treatments to each person’s unique genetic makeup and specific biological markers.
A seminal early example came in the late 1990s with the cancer drug trastuzumab (Herceptin), an antibody therapy effective only in breast cancer patients whose tumors overexpress the HER2 gene. Herceptin’s approval guided by a companion genetic test for HER2 marked the first FDA-approved therapy explicitly tailored to a genetic subgroup.² This demonstrated that understanding a patient’s genes could dramatically improve treatment efficacy, ushering in a “targeted therapy” paradigm.
Since then, the sequencing of the human genome and the advent of high-throughput technologies have yielded a trove of biomarkers and gene variants linked to disease and drug response. Oncology has led the way – today targeted therapies are available for breast, lung, colorectal cancers and more, each home in on specific molecular drivers.³
Personalized medicine isn’t limited to cancer. In areas like heart health, mental health, and more, scientists have found that our genes can affect how we respond to certain medications.This enables doctors to select more effective treatments while minimizing potential side effects. For drug companies, it also means they can create more targeted medicines for specific groups of patients, often with better success during clinical trials. In fact, many new drugs today include genetic information on their labels to guide treatment. According to the Personalized Medicine Coalition, about one in four recently approved drugs is tied to a specific genetic marker. What started as a new idea has now become a key part of how medicines are developed — and with the help of AI, it’s only going to grow.
How AI Is Speeding Up Genomics-Based Drug Discovery
Genomics gives us the biological blueprint of diseases, but making sense of this complex information isn’t easy. That’s where AI steps in. With its power to quickly analyze massive datasets, AI is transforming how we discover and develop new medicines, especially those tailored to a person’s genetic profile.
1. Finding New Drug Targets Faster
Traditionally, discovering the right gene or protein to target with a drug was like searching for a needle in a haystack. AI can scan through millions of genetic variations and other biological data in a matter of hours. This kind of analysis could take human researchers years.
Using machine learning models, scientists can now quickly spot patterns and identify genes or protein...
(All Rights Reserved)